173 related articles for article (PubMed ID: 33792689)
1. Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions.
Zuurbier CJ; Baartscheer A; Schumacher CA; Fiolet JWT; Coronel R
Cardiovasc Res; 2021 Dec; 117(14):2699-2701. PubMed ID: 33792689
[No Abstract] [Full Text] [Related]
2. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
[TBL] [Abstract][Full Text] [Related]
3. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
[TBL] [Abstract][Full Text] [Related]
5. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
7. Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.
Bayes-Genis A; Iborra-Egea O; Spitaleri G; Domingo M; Revuelta-López E; Codina P; Cediel G; Santiago-Vacas E; Cserkóová A; Pascual-Figal D; Núñez J; Lupón J
Sci Rep; 2021 Jun; 11(1):12025. PubMed ID: 34103605
[TBL] [Abstract][Full Text] [Related]
8. A role for tubular Na
Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
Mustroph J; Wagemann O; Lücht CM; Trum M; Hammer KP; Sag CM; Lebek S; Tarnowski D; Reinders J; Perbellini F; Terracciano C; Schmid C; Schopka S; Hilker M; Zausig Y; Pabel S; Sossalla ST; Schweda F; Maier LS; Wagner S
ESC Heart Fail; 2018 Aug; 5(4):642-648. PubMed ID: 30117720
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes.
Pabel S; Reetz F; Dybkova N; Shomroni O; Salinas G; Mustroph J; Hammer KP; Hasenfuss G; Hamdani N; Maier LS; Streckfuss-Bömeke K; Sossalla S
J Mol Med (Berl); 2020 Dec; 98(12):1689-1700. PubMed ID: 33034709
[TBL] [Abstract][Full Text] [Related]
12. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Packer M
Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
[No Abstract] [Full Text] [Related]
13. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.
Ng KM; Lau YM; Dhandhania V; Cai ZJ; Lee YK; Lai WH; Tse HF; Siu CW
Sci Rep; 2018 Oct; 8(1):14872. PubMed ID: 30291295
[TBL] [Abstract][Full Text] [Related]
14. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
Li X; Römer G; Kerindongo RP; Hermanides J; Albrecht M; Hollmann MW; Zuurbier CJ; Preckel B; Weber NC
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205045
[TBL] [Abstract][Full Text] [Related]
15. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
16. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.
Barış VÖ; Dinçsoy AB; Gedikli E; Zırh S; Müftüoğlu S; Erdem A
Cardiovasc Toxicol; 2021 Sep; 21(9):747-758. PubMed ID: 34089496
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin Attenuates Na
Ye Y; Jia X; Bajaj M; Birnbaum Y
Cardiovasc Drugs Ther; 2018 Dec; 32(6):553-558. PubMed ID: 30367338
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Filippatos TD; Liontos A; Papakitsou I; Elisaf MS
Postgrad Med; 2019 Mar; 131(2):82-88. PubMed ID: 30757937
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin directly improves diastolic function in human heart failure.
Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
